Previous 10 | Next 10 |
Anavex Life Sciences press release ( NASDAQ: AVXL ): Q3 GAAP EPS of -$0.16 beats by $0.01 . Cash and cash equivalents of $153.2 million on June 30, 2022, compared to $152.1 million at fiscal year end September 30, 2021. For further details see: Anavex Life Sc...
Company to host a webcast today at 4:30 p.m. Eastern Time NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differ...
NEW YORK, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diso...
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diso...
Clinical-stage biotech Anavex Life Sciences ( NASDAQ: AVXL ) added ~7% in early pre-market trading Monday after the company disclosed results to highlight the impact of its lead candidate ANAVEX2-73 on the neurodegenerative genes of both Alzheimer’s and Parkinson...
GeoVax Labs ( GOVX ) +57% . Mobile Global Esports (MGAM) +45% . Celyad Oncology ( CYAD ) +40% as FDA lifts hold on colorectal cancer trial of CYAD-101/Keytruda. Virax Biolabs Group ( VRAX ) +38% . Aethlon Medical ( AEMD ) +35...
Expression levels of pathological dysregulated neurodegenerative genes of both Alzheimer’s and Parkinson’s disease were significantly restored by the therapeutic effect of ANAVEX®2-73 (p<0.005) These findings will facilitate contextualization of upcoming re...
INmune Bio and Alector are seeking to treat Alzheimer's disease by decreasing neuroinflammation while maintaining a healthy immune response. However, neither company's drug candidate appears to address the oxidative stress that precedes neuroinflammation. Anti-inflammatory drug ca...
Mid- and late-stage data readouts over the last few years for Alzheimer's therapies have had a similar theme: Failure. Almost all these candidates have one thing in common: They target reducing beta-amyloid plaque in the brain that is thought to play a role in the memory-robbing dis...
Anavex Life Sciences Corp. (NASDAQ:AVXL) added ~5% in the pre-market Thursday after Berenberg initiated the coverage on the clinical-stage biotech with a Buy recommendation noting the underappreciated potential of a central nervous system medication. The company “is developin...
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
2024-07-18 02:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsyc...